Please assess the completion status of the following clinical trial:

Trial Title: Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed and written informed consent form~2. ≥ 19 years of age~3. Histologically or cytologically confirmed cholangiocarcinoma~4. Documented metastatic disease~5. At least one measurable lesion according to the RECIST v1.1~6. Disease progression on gemcitabine-cisplatin combination therapy~7. For patients whose disease recurred after curative resection (R0 or R1), previous adjuvant 5-FU-based chemotherapy is allowed if there is at least 6 month-interval between the last dose of adjuvant chemotherapy and recurrence of disease.~8. Adequate hepatic, renal and hematological function AST(Aspartate Aminotransferase), ALT(Alanine Aminotransferase) ≤ 100 IU/L (100 U/L), Cr(Creatinine) ≤ 1.5mg/dL~9. Eastern Cooperative Oncology Group (ECOG) Performance status 0-1~Exclusion Criteria:~1. Serum total bilirubin ≥2 x ULN(upper limit of normal) (biliary drainage is allowed for biliary obstruction)~2. Severe renal impairment (Clcr ≤ 30 ml/min)~3. Inadequate bone marrow reserves as evidenced by:~   * ANC(Absolute Neutrophile Count) ≤ 1,500 cells/μl; or~  * Platelet count ≤ 100,000 cells/μl; or~  * Hemoglobin ≤ 9 g/dL~4. ECOG performance status 2-4~5. Any clinically significant disorder impacting the risk-benefit balance negatively per physician's judgment~6. Any clinically significant gastrointestinal disorder, including hepatic disorders, bleeding, inflammation, occlusion, or diarrhea \> grade 2~7. Severe arterial thromboembolic events (myocardial infarction, unstable angina pectoris, stroke) in last 6 months~8. NYHA(New York Heart Association) Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure. Or known abnormal ECG with clinically significant abnormal findings~9. Active infection or an unexplained fever \>38.5°C (excluding tumor fever), which in the physician's opinion might compromise the patient's health~10. Current use or any use in last two weeks of strong CYP3A-enzyme inducers/inhibitors and/or strong UGT1A inhibitors~11. Known hypersensitivity to any of the components of Onivyde other liposomal irinotecan formulations, irinotecan, fluoropyrimidines, or leucovorin.~12. Breast feeding, known pregnancy, positive serum pregnancy test or unwillingness to use an effective method of contraception, during therapy and for 3 months following the last dose of Onivyde. Females of Childbearing Potential must either agree to use and be able to take effective contraceptive birth control measures (Pearl Index \< 1) or agree to practice complete abstinence from heterosexual intercourse during the course of the study and for at least 3 months after last application of program treatment. A female subject is considered to be of childbearing potential unless she is age ≥ 50 years and naturally amenorrhoeic for ≥ 2 years, or unless she is surgically sterile. Males must agree not to father a child (including not donating sperm) during the course of the trial and for at least 6 months after last administration of study drugs.~13. Previous treatment with combination drug tegafur, gimeracil, and oteracil potassium with seven days before enrollment.~14. Current treatment with Sorivudine.~15. Severe fatigue or bone marrow depression after prior radiotherapy or antineoplastic therapy~16. Pregnancy or women with child-bearing potential or lactating~17. Non-malignant severe co-morbidity~18. Previous second-line anti-cancer therapy (e.g., Tegafur)~19. History of other malignancy with a disease-free interval \<5 years (Registration is permitted if it has minimal impact on prognosis, such as carcinoma in situ and papillary thyroid cancer)~20. History or current eveidence of brain metastasis

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5-FU/LV/Onivyde (Type: EXPERIMENTAL): Onivyde 70 mg/m2 (90 minutes), dl-LV 400mg/m2 or l-LV 200mg/m2 (30 minutes), 5-FU 2400 mg/m2 (46 hours) IV every 2 weeks.
- 5FU/LV (Type: ACTIVE_COMPARATOR): dl-LV 400mg/m2 or l-LV 200mg/m2 (30 minutes), 5-FU 2400 mg/m2 (46 hours) IV every 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).